Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Issues Negative Opinion For Novartis’ Anti-Infective Mycograb

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm also receives positive opinions from EU authorities on hypertension combo Exforge and macular degeneration treatment Lucentis.
Advertisement

Related Content

Novartis To Launch Exforge In September 2007
Novartis To Launch Exforge In September 2007
Daiichi Sankyo Submits Benicar/Amlodipine Fixed-Dose Combination To FDA
Noxafil Gains Additional Oropharyngeal Candidiasis Indication
Noxafil Gains Additional Oropharyngeal Candidiasis Indication
Novartis’ Newly Licensed Antidepressant Hits Snag In EU Under Separate Sponsor
Novartis Could Add To Its Hospital-Acquired Infection Portfolio With Acquisition
Novartis’ Exforge Has Late December User Fee Date
Schwarz To Patch Up Neupro NDA Within Six Months Following “Approvable” Letter
Pfizer To Spring Forward With Eraxis Launch

Topics

Advertisement
UsernamePublicRestriction

Register

PS063390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel